Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelly L Warfield

Showing results (1-10 of 101) with videos related to

Pageof 11
Sort By:
Expert Review of Vaccines|March 22, 2016
Role of small biotechnology companies in the fledgling biodefense vaccine industryKelly L Warfield, M Javad Aman
The Journal of Infectious Diseases|October 12, 2011
Advances in virus-like particle vaccines for filovirusesKelly L Warfield, M Javad Aman
Viruses|November 22, 2012
Mouse models for filovirus infectionsSteven B Bradfute, Kelly L Warfield, Mike Bray
Journal of the American Veterinary Medical Association|May 2, 2009
Filovirus infectionsKelly L Warfield, Emily M Deal, Sina Bavari
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2008
Functional CD8+ T cell responses in lethal Ebola virus infectionSteven B Bradfute, Kelly L Warfield, Sina Bavari
Frontiers in Bioscience (Landmark Edition)|January 29, 2022
UV-4B potently inhibits replication of multiple SARS-CoV-2 strains in clinically relevant human cell linesEvelyn J Franco, Kelly L Warfield, Ashley N Brown
Expert Review of Vaccines|July 20, 2005
Filovirus-like particles as vaccines and discovery toolsKelly L Warfield, Dana L Swenson, Gretchen Demmin, et al.
Journal of Virology|February 4, 2011
Key genomic changes necessary for an in vivo lethal mouse marburgvirus variant selection processLoreen L Lofts, Jay B Wells, Sina Bavari, et al.
Virology Journal|August 29, 2009
Discovery of common marburgvirus protective epitopes in a BALB/c mouse modelWarren V Kalina, Kelly L Warfield, Gene G Olinger, et al.
Current Opinion in Molecular Therapeutics|April 14, 2006
Antisense treatments for biothreat agentsKelly L Warfield, Rekha G Panchal, M Javad Aman, et al.
Pageof 11

Showing results (1-10 of 101) with videos related to

Sort By:
Pageof 11
Expert Review of Vaccines|March 22, 2016
Role of small biotechnology companies in the fledgling biodefense vaccine industryKelly L Warfield, M Javad Aman
The Journal of Infectious Diseases|October 12, 2011
Advances in virus-like particle vaccines for filovirusesKelly L Warfield, M Javad Aman
Viruses|November 22, 2012
Mouse models for filovirus infectionsSteven B Bradfute, Kelly L Warfield, Mike Bray
Journal of the American Veterinary Medical Association|May 2, 2009
Filovirus infectionsKelly L Warfield, Emily M Deal, Sina Bavari
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2008
Functional CD8+ T cell responses in lethal Ebola virus infectionSteven B Bradfute, Kelly L Warfield, Sina Bavari
Frontiers in Bioscience (Landmark Edition)|January 29, 2022
UV-4B potently inhibits replication of multiple SARS-CoV-2 strains in clinically relevant human cell linesEvelyn J Franco, Kelly L Warfield, Ashley N Brown
Expert Review of Vaccines|July 20, 2005
Filovirus-like particles as vaccines and discovery toolsKelly L Warfield, Dana L Swenson, Gretchen Demmin, et al.
Journal of Virology|February 4, 2011
Key genomic changes necessary for an in vivo lethal mouse marburgvirus variant selection processLoreen L Lofts, Jay B Wells, Sina Bavari, et al.
Virology Journal|August 29, 2009
Discovery of common marburgvirus protective epitopes in a BALB/c mouse modelWarren V Kalina, Kelly L Warfield, Gene G Olinger, et al.
Current Opinion in Molecular Therapeutics|April 14, 2006
Antisense treatments for biothreat agentsKelly L Warfield, Rekha G Panchal, M Javad Aman, et al.
Pageof 11